TECHNOLOGY FOR SOCIAL IMPACT

We share a mission

Improve the quality of life of the people

We are an interdisciplinary group that works to make technologies that provide a better quality of life to the people. Our motivation is people, so we work hard to improve day by day with you. Get to know us.

David Blánquez

CEO

Jordina Arcal

Deputy CEO

Jesús Valls

COO

Clara Gelabert 

CFO

Xavier Raurich 

CTO

Josep Lluís Arcos

CSO

Fernando Atienza 

Quality Manager

Lluís Munsó

AI Engineer

Dra. Gloria Durán

Chief Medical Officer

Dr. Gustavo Torres

Neurologist

Alex Lopez

AI Engineer

Marina Blánquez

Marketing Assistant

Anna Calixto

Customer relations

Jessica Borrell

Administrative

PhD Beatriz López

PhD Artificial Intelligence

Luismi Aras

Dr. Medicina, CEO Apoyo Dravet

Adrián Trejo

Director Neurociencias Corachan

David David Blánquez CEO Jordina Jordina Arcal Deputy CEO Management

Jesus Jesús Valls COO Clara Clara Gelabert CFO Xavi Xavier Raurich CTO Fernando Fernando Atienza Quality Manager Josep Lluis Josep Lluís Arcos CSO Lluis Lluís Munsó AI Engineer Alex Alex López AI Engineer Jessica Jessica Borrell Administrative Gloria Dra. Gloria Durán Chief Medical Officer Gustavo Dr. Gustavo Torres Neurologist Marina Marina Blánquez
Marketing Assistant
Anna Calixto Anna Calixto Customer relations
Team

Beatriz PhD Beatriz López PhD Artificial Intelligence Luismi Luismi Aras Dr. Medicina, CEO Apoyo Dravet Adrian Adrián Trejo Director Neurociencias Corachan Advisory Board
An unquestionable objective

We have very clear objectives.

We only understand technological development if it has a social impact, which is why we spend part of our income to R+D projects and part of our profits to social action.

mjn-neuro has a positive impact on our society, as we explain in our Theory of Social Change. Also, we will periodically measure our impact and publish the results obtained. Discover the importance of social change in MJN.

5

of our profit will be dedicated to promote social projects

10

of our sales will go to research and innovation

Awards and recognitions

This international certificate recognizes that mjn-neuro is compliant with all requirements specified to sell and provide medical products and services.

This certificate indicates that the solution developed by mjn-neuro to evaluate the risk of epilepsy seizures is a medical device that complies with directive 93/42/EEC.

Our commitment to excellence

Everything we do in mjn-neuro is compliant with the highest quality standards.

mjn-neuro has the ISO 13485:2016 quality certificate, the Manufacturer’s License from the Spanish Agency of Medicines and Health Products and the CE certificate as a class IIa medical device. You can also read our quality policy here.

Our team

Get to know the mjn-neuro team

Corporation

Women engineers

You already know us and mjn-neuro is committed both to innovation in technology and to the social impact of each…
Team

CLARA GELABERT Interview

We interviewed Clara Gelabert, our CFO. She has been part of the mjn-neuro team for more than two years...
Corporation

Milestones 2020

We are coming to the end of 2020, we would like to congratulate everyone who has helps us in our…
See all the interviews

Do you imagine being able to know at any time the risk of suffering a seizure?

Our collaborators

We are not alone helping people with epilepsy

Grant programs

EIT Health (European Institute of Innovation and Technology) and the European Union, Start-up Amplifier Instrument. Grant 220445

PROJECT: IMPROVING QUALITY OF LIFE FOR PEOPLE WITH EPILEPSY IN EUROPE
CONSORTIUM: MJN-NEURO (SPAIN), OXFORD UNIVERSITY HOSPITAL NHS FOUNDATION TRUST (UNITED KINGDOM), DIAKONIE KORK (GERMANY), CLÍNICA UNIVERSIDAD DE NAVARRA (SPAIN), SYNAPTIA (SPAIN), DKV SALUD (SPAIN), MEDTRONIC ( SPAIN), MEDICAL VALLEY (GERMANY), IESE BUSINESS SCHOOL (SPAIN), BIOCAT (SPAIN) AND DKV INTEGRALIA FOUNDATION (SPAIN).

With this European grant of 2.76 million euros, mjn-neuro intends to enter the European market with its mjn-SERAS device, the world’s first device capable of providing early warning of an epileptic seizure.

See more

Proyecto CPP2021-008311

VISOR EEG (dispositiVo regIStro hOlter seRas EEG)

The main objective of the project is the creation of an out-of-hospital Holter EEG recording system using portable, discreet and non-invasive devices, so that the patient can carry out daily life activities at the same time as their brain electrical activity is recorded, in an easier and more comfortable way for the patient. In addition, this system will provide the analysis of quantitative and qualitative characteristics of the EEG signal using artificial intelligence algorithms.

Proyecto ICEXNP_202102281388

Estrategia internacional para mjn-SERAS

ICEXNEXT Program

Project for the development of an international strategy in the area of business, marketing and general management, for the product mjn-SERAS for epilepsy. Considering market identification, product niche, competition and marketing channels.
Carried out in collaboration with consultant Wilhelm Lappe.
Project subsidized by the EUROPEAN REGIONAL DEVELOPMENT FUND (ERDF). A way of doing Europe.

Program "Cupons a la innovació 2020 ACCIÓ" Generalitat de Catalunya

Alzhemeir's detection device prototype

The project subsidized by Acció aims to develop a functional prototype capable of recording the brain activity of any person in a fast, simple and portable way in a standardized way, without any type of customization and whose design allows batches to achieve economies of scale.
File: ACE008/20/000316

"Misiones CDTI" program

Project: Dreamer: EARLY DETECTION OF ALZHEIMER'S

Project for the early detection of signs that allow the diagnosis of Alzheimer’s disease in the preclinical phase, through cognitive markers and electroencephalographic records, with the development of a portable and
non-invasive device and the use of artificial intelligence.

The project has a duration of three years (01/10/2020 – 31/12/2022) and is carried out entirely in Catalonia by the participants ELAUSA ELECTRONICA I AUTOMATISMES S.L., INSTITUTO MEDICO PRIVADO, S.L.P., MJN NEUROSERVEIS S.L. y WEIRD KIN S.L.
It has a budget of €2,095,799 and a grant of €1,444,491.15.
Document: EXP 00135659 / MIP_20201050
DREAMER is a project subsidised by the CDTI with the support of the Ministry of Science and Innovation.

Subsidised by CDTI

Retos Colaboración MJN-eXiT (Universitat de Girona)

Project: mjn-SERAS, Device for the evaluation of the risk of epileptic seizures

The main objective of the project is to improve the quality of life of patients with epilepsy through the development of a solution that will be capable of detecting and alerting epilepsy seizures suffered by this type of patient and thereby avoiding accidents resulting from these situations.

To achieve this objective, the project collaborates with the company mjn-neuro, which will take the lead into this initiative. The project will also count on the UDG eXiT Research Group who has a long experience in creating predictive methods from biomedical data.

Project funded by FEDER / Ministry of Science, Innovation, and Universities – State Research Agency / Project (RTC-2017-6701-1).

The main objective of this call is to promote technological development, innovation and quality research.

See more

Horizon 2020, SME Instruments 2018-2020. Grant 849781

Project: Seizure Risk Assessment for epilepsy
See more
Stories

From the people who best know about epilepsy

A world of inspiration
Blog

At mjn-neuro talk about epilepsy in all forums and all languages

Go to blog